Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques

Details

• Alternative Title:
  J Infect Dis
• Personal Author:
  Makarova, Natalia ; Singletary, Tyana ; Peet, M. Melissa ; Mitchell, James ; Bachman, Shanon ; Holder, Angela ; Dinh, Chuong ; Lipscomb, Jonathan ; Agrahari, Vivek ; Mendoza, Maria ; Pan, Yi ; Heneine, Walid ; Clark, Meredith R. ; García-Lerma, J. Gerardo ; Doncel, Gustavo F. ; Smith, James M.
• Description:
  Vaginal inserts that can be used on demand before or after sex may be a desirable human immunodeficiency virus (HIV) prevention option for women. We recently showed that inserts containing tenofovir alafenamide fumarate (TAF, 20 mg) and elvitegravir (EVG, 16 mg) were highly protective against repeated simian/human immunodeficiency virus (SHIV) vaginal exposures when administered to macaques 4 hours before or after virus exposure (93% and 100%, respectively). Here, we show in the same macaque model that insert application 8 hours or 24 hours after exposure maintains high efficacy (94.4% and 77.2%, respectively). These data extend the protective window by TAF/EVG inserts and inform their clinical development for on-demand prophylaxis in women.
• Subjects:
  Adenine Administration, Intravaginal Alanine Animals Anti-HIV Agents Disease Models, Animal Female HIV Infections Macaca Mulatta Quinolones Simian Acquired Immunodeficiency Syndrome Simian Immunodeficiency Virus Tenofovir Vagina

  More +
• Keywords:
  Elvitegravir HIV Preexposure And Postexposure Prophylaxis Macaque Models Tenofovir Alafenamide Topical PrEP And PEP
• Source:
  J Infect Dis. 229(6):1791-1795
• Pubmed ID:
  38134382
• Pubmed Central ID:
  PMC11457164
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/ ; CC/CDC HHSUnited States/
• Volume:
  229
• Issue:
  6
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:4849b990142b4c0090a1038299a239b3577b55b9e1cb3ac1b9ec4f0f84858e7078654404f595f317afb724b02c37f792aa49a2f4d842fe664f38b8392d8fece8
• Download URL:
  https://stacks.cdc.gov/view/cdc/164673/cdc_164673_DS1.pdf
• File Type:
  [PDF - 422.01 KB ]